Literature DB >> 20087880

K-ras exon 4A has a tumour suppressor effect on carcinogen-induced murine colonic adenoma formation.

Feijun Luo1, Hongtao Ye, Rifat Hamoudi, Gehong Dong, Wenyan Zhang, Charles E Patek, George Poulogiannis, Mark J Arends.   

Abstract

K-ras encodes two isoforms, K-ras 4A and 4B, that are jointly affected by K-ras activating mutations, which are prevalent in colorectal cancer (CRC). CRC shows alterations in the expressed K-ras 4A : 4B isoform ratio in favour of K-ras 4B, in tumours both with and without K-ras mutations. The present study evaluated whether K-ras 4A expression can suppress colonic adenoma development in the absence of its oncogenic allele. Mice with homozygous targeted deletions of K-ras exon 4A (K-ras(tmDelta4A/tmDelta4A)) that can express the K-ras 4B isoform only, along with heterozygous K-ras(tmDelta4A/+) and wild-type mice, were given ten weekly 1,2-dimethylhydrazine (DMH) treatments to induce colonic adenomas. There was a significant increase in both the number and the size of colonic adenomas in DMH-treated K-ras(tmDelta4A/tmDelta4A) mice, with reduced survival, compared with heterozygous and wild-type mice. No K-ras mutations were found in any of the 30 tumours tested from the three groups. Lack of expression of K-ras 4A transcripts was confirmed, whereas the relative expression levels of K-ras 4B transcripts were significantly increased in the adenomas of K-ras(tmDelta4A/tmDelta4A) mice compared with K-ras(tmDelta4A/+) and wild-type mice. Immunohistochemical studies showed that adenomas of K-ras(tmDelta4A/tmDelta4A) mice had significantly increased cell proliferation and significantly decreased apoptosis with evidence of activation of MapKinase and Akt pathways, with increased phospho-Erk1/2 and both phospho-Akt-Thr308 and phospho-Akt-Ser473 immunostaining, compared with adenomas from K-ras(tmDelta4A/+) and wild-type mice. In conclusion, following DMH treatment, K-ras exon 4A deletion promoted increased number and size of colonic adenomas showing increased K-ras 4B expression, increased proliferation, decreased apoptosis, and activation of MapKinase and Akt pathways, in the absence of K-ras mutations. Therefore, K-ras 4A expression had a tumour suppressor effect on carcinogen-induced murine colonic adenoma formation, explaining the selective advantage of the altered K-ras 4A : 4B isoform ratio found in human colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20087880     DOI: 10.1002/path.2672

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  12 in total

1.  Hypoxia regulates alternative splicing of HIF and non-HIF target genes.

Authors:  Johnny A Sena; Liyi Wang; Lynn E Heasley; Cheng-Jun Hu
Journal:  Mol Cancer Res       Date:  2014-05-21       Impact factor: 5.852

2.  K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif.

Authors:  Frederick D Tsai; Mathew S Lopes; Mo Zhou; Helen Court; Odis Ponce; James J Fiordalisi; Jessica J Gierut; Adrienne D Cox; Kevin M Haigis; Mark R Philips
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-05       Impact factor: 11.205

3.  Activation of K-RAS by co-mutation of codons 19 and 20 is transforming.

Authors:  Adam Naguib; Catherine H Wilson; David J Adams; Mark J Arends
Journal:  J Mol Signal       Date:  2011-03-03

4.  K-ras 4A and 4B mRNA levels correlate with superoxide in lung adenocarcinoma cells, while at the protein level, only mutant K-ras 4A protein correlates with superoxide.

Authors:  Richard J Calvert; Meghana Gupta; Anna Maciag; Yih-Horng Shiao; Lucy M Anderson
Journal:  Lung Cancer       Date:  2013-03-06       Impact factor: 5.705

5.  Comparison of the Conformations of KRAS Isoforms, K-Ras4A and K-Ras4B, Points to Similarities and Significant Differences.

Authors:  Mayukh Chakrabarti; Hyunbum Jang; Ruth Nussinov
Journal:  J Phys Chem B       Date:  2016-01-27       Impact factor: 2.991

6.  Wild-type K-ras has a tumour suppressor effect on carcinogen-induced murine colorectal adenoma formation.

Authors:  Feijun Luo; George Poulogiannis; Hongtao Ye; Rifat Hamoudi; Gehong Dong; Wenyan Zhang; Ashraf E K Ibrahim; Mark J Arends
Journal:  Int J Exp Pathol       Date:  2013-12-20       Impact factor: 1.925

7.  Deep-sequencing analysis of the mouse transcriptome response to infection with Brucella melitensis strains of differing virulence.

Authors:  Fangkun Wang; Sen Hu; Wenxing Liu; Zujian Qiao; Yuzhe Gao; Zhigao Bu
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

8.  Comparison of liver oncogenic potential among human RAS isoforms.

Authors:  Sook In Chung; Hyuk Moon; Hye-Lim Ju; Dae Yeong Kim; Kyung Joo Cho; Silvia Ribback; Frank Dombrowski; Diego F Calvisi; Simon Weonsang Ro
Journal:  Oncotarget       Date:  2016-02-09

9.  Role of epigenetic factors in the selection of the alternative splicing isoforms of human KRAS in colorectal cancer cell lines.

Authors:  Ángela L Riffo-Campos; Francisco Gimeno-Valiente; Fernanda M Rodríguez; Andrés Cervantes; Gerardo López-Rodas; Luis Franco; Josefa Castillo
Journal:  Oncotarget       Date:  2018-04-17

Review 10.  Splice variants of RAS-translational significance.

Authors:  Erzsébet Rásó
Journal:  Cancer Metastasis Rev       Date:  2020-08-08       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.